According to Quest Diagnostics
's latest financial reports the company has a price-to-book ratio of 2.30.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2023-12-31 | 2.42 | -18.56% |
2022-12-31 | 2.97 | -8.3% |
2021-12-31 | 3.23 | 38.78% |
2020-12-31 | 2.33 | -5.43% |
2019-12-31 | 2.46 | 17.16% |
2018-12-31 | 2.10 | -21.1% |
2017-12-31 | 2.67 | -0.87% |
2016-12-31 | 2.69 | 26.46% |
2015-12-31 | 2.13 | -4.63% |
2014-12-31 | 2.23 | 14.93% |
2013-12-31 | 1.94 | -11.95% |
2012-12-31 | 2.20 | -10.61% |
2011-12-31 | 2.47 | 8.49% |
2010-12-31 | 2.27 | -17.62% |
2009-12-31 | 2.76 | -2.05% |
2008-12-31 | 2.82 | -8.83% |
2007-12-31 | 3.09 | -9.25% |
2006-12-31 | 3.40 | -7.92% |
2005-12-31 | 3.70 | -12.48% |
2004-12-31 | 4.23 | 34.6% |
2003-12-31 | 3.14 | -0.39% |
2002-12-31 | 3.15 |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
LabCorp LH | 2.33 | 1.41% | ๐บ๐ธ USA |
Psychemedics PMD | 2.34 | 2.04% | ๐บ๐ธ USA |
NeoGenomics
NEO | 2.13 | -7.21% | ๐บ๐ธ USA |
Qiagen QGEN | 2.50 | 8.84% | ๐ณ๐ฑ Netherlands |
Enzo Biochem ENZ | 0.9192 | -59.97% | ๐บ๐ธ USA |